Chief Executive Officer at Carpe Vitae, Dr Rosalind (Ros) Wilson is a graduate of Monash Medical School and holds an MBA from London Business School, bringing a wealth of scientific and commercial experience to Carpe Vitae. Prior to joining Carpe Vitae, Dr Wilson has had a successful career in the global pharmaceutical and biotechnology sector, focused on clinical development, commercialisation and lifecycle management of new medicines.
After a brief stint in clinical practice, Dr Wilson worked in a variety of roles for F. Hoffman-La Roche (Roche) in Australia, the United Kingdom and Switzerland, including leading the team that successfully developed prescription treatment PERJETA® (pertuzumab) for patients with HER2-overexpressing breast cancer.
Since returning to Australia in 2009, Dr Wilson has consulted to a range of pharmaceutical and biotechnology companies both locally and overseas, with a focus on clinical research, product lifecycle and pipeline strategy. She has also led clinical research for lung cancer in the non-profit sector and served as Chief Executive Officer for Factor Therapeutics (ASX: FTT) and as Global Head of Drug Development for Telix Pharmaceuticals (ASX: TLX).
Director and Co-Founder of Carpe Vitae, Professor Kenneth O’Byrne is a globally respected medical oncologist and clinical scientist. He has published over 400 peer-reviewed manuscripts and patented novel anti-cancer therapeutics and predictive biomarker tests developed in both Australia and Ireland.
In addition to his work with Carpe Vitae, Professor O’Byrne is also the Founder of the British Thoracic Oncology Group (BTOG), Co-Founder of the European Thoracic Oncology Platform (ETOP), a member of the European Society for Medical Oncology (ESMO) Investigational Immunotherapy and International Association for the Study of Lung Cancer (IASLC) fellowship committees, Board member of the International Mesothelioma Interest Group (iMig), scientific committee member of the International Liquid Biopsy Society (ILBS) and Thoracic Oncology Group Australia (TOGA), and is a Chief Investigator on the Australian Genomic Cancer Medicine Program (GCMP).
Director and Co-Founder of Carpe Vitae, Professor Derek Richard is an experienced cancer and ageing researcher, with expertise in drug development and genomics. In his various scientific directorship roles, he is responsible for leading a group of more than 50 scientists, clinicians and students.
Professor Richard has published over 130 manuscripts including journal articles in leading publications including Nature, Molecular Cell, Nature Communications, Proceedings of the National Academy of Sciences and Genes & Development, and has been awarded more than $25 million in research funding since 2015.
His research focusses on the link between the DNA damage response, ageing and cancer, spanning basic discovery biology through to translation into clinical practice.
Co-Founder and Scientific Lead at Carpe Vitae, Dr Emma Bolderson has almost 20 years’ experience in the genome stability research field.
Dr Bolderson gained her PhD in cancer cell biology from the University of Sheffield, UK in 2005. Emma moved to Australia in 2005, joining QIMR Berghofer as a postdoctoral fellow, before being recruited to Queensland University of Technology in 2012.
Dr Bolderson’s work focuses on the mechanisms by which our cells detect and repair DNA damage, chromatin remodelling, cancer biology, cell metabolism, and drug design and development. Dr Bolderson’s research team strives to identify the cellular mechanisms that drive the ageing process, to ultimately identify new therapies to alleviate ageing-related diseases. She has published over 40 papers in leading journals including Nature, Nature Communications and Nucleic Acids Research.